Fisher to sell diaDexus' PLAC in US:
This article was originally published in Clinica
Executive Summary
Diagnostics firm diaDexus is set to make its automated PLAC blood test available in the US through Fisher HealthCare. Fisher will sell the test, which was cleared for use with Hitachi, Hitachi Roche P-Modular and Olympus chemistry analysers by the FDA in February 2008 (see Clinica No 1296, p 26), to US hospital clinical laboratories. According to South San Francisco, California-based diaDexus, the product is the only FDA-cleared blood test to asses risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. Financial details of the deal were not disclosed.
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.